SCHEMBL25277572

SCHEMBL25277572

FC(F)(F)C(F)(F)c1ccc2ncnc(N3CC4(CCNCC4)C3)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.44
▸ CYP1A2 P05177 12/20 0.39
▸ CYP3A4 P08684 11/20 0.39
▸ CLK4 Q9HAZ1 8/20 0.39
▸ CYP2C19 P33261 7/20 0.39
▸ HSD17B10 Q99714 7/20 0.39
▸ ALDH1A1 P00352 6/20 0.39
▸ HPGD P15428 4/20 0.39
▸ USP2 O75604 4/20 0.39
▸ CYP2D6 P10635 3/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ MAPT P10636 2/20 0.39
▸ LMNA P02545 4/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ TSHR P16473 4/20 0.36
▸ AKT1 P31749 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25222339 0.81 HTT (0.44) HTTCYP1A2CYP3A4CLK4CYP2C19
SCHEMBL30455740 0.81 HTT (0.44) HTTCYP1A2CYP3A4CLK4CYP2C19
SCHEMBL25275560 0.81 PIM1 (0.48) HTTCYP1A2CYP3A4CLK4CYP2C19
Hydrochloric Acid SCHEMBL25278259 0.80 HTT (0.43) HTTCYP1A2CYP3A4CLK4CYP2C19
SCHEMBL25273633 0.76 ALDH1A1 (0.51) HTTCYP1A2CYP3A4CLK4CYP2C19
SCHEMBL31501706 0.76 HTT (0.43) HTTCYP1A2CYP3A4CLK4CYP2C19
SCHEMBL30404904 0.75 HTT (0.39) HTTCYP1A2CYP3A4CLK4CYP2C19
SCHEMBL25233084 0.74 CYP1A2 (0.47) HTTCYP1A2CYP3A4CLK4CYP2C19
SCHEMBL25225518 0.74 HSD17B10 (0.36) HTTCYP1A2CYP3A4CLK4HSD17B10
SCHEMBL25227852 0.74 HTT (0.44) HTTCYP1A2CYP3A4CLK4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
EP-4444300-A2 INHIBITORS OF MENIN-MLL INTERACTION Bala Therapeutics, Inc. (US) 2024-10-16 — — EP disclosed
CN-118647378-A Inhibitors of Mei Nen protein interaction with MLL 巴拉疗法公司 2024-09-13 — — CN disclosed
WO-2023107696-A2 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION MLLT1, MEN1, BMI1 HTT 3578/4885CYP1A2 3937/4885CYP3A4 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback